预防宫颈癌与减少筛查危害——美国患者和临床医生更倾向于什么，他们的偏好重要吗？
Protection against cervical cancer versus decreasing harms from screening - What would U.S. patients and clinicians prefer, and do their preferences matter?
作者信息
Kinney Walter K, Huh Warner K
机构信息
Department of Women's Health, The Permanente Medical Group, 650 Response Road, Sacramento, CA 95815, USA.
Division of Gynecologic Oncology, University of Alabama at Birmingham, 1700 6th Avenue South, WIC Room 10250, Birmingham, AL, USA.
出版信息
Prev Med. 2017 May;98:31-32. doi: 10.1016/j.ypmed.2016.12.041. Epub 2017 Feb 6.
Abstract
The primary goal for many providers in the United States has been to deliver the level of protection against cervical cancer afforded by annual cervical cytology while improving screening test performance. Adoption of recent screening recommendations has been inconsistent and has created considerable consternation and confusion. This editorial addresses the perspective of U.S. patients and providers and how their preferences may run counter to current screening recommendations.
摘要
美国许多医疗服务提供者的首要目标一直是在提高筛查测试性能的同时，提供年度宫颈细胞学检查所带来的宫颈癌防护水平。对近期筛查建议的采纳情况并不一致，引发了相当多的担忧和困惑。这篇社论探讨了美国患者和医疗服务提供者的观点，以及他们的偏好可能如何与当前的筛查建议背道而驰。
相似文献
1
Protection against cervical cancer versus decreasing harms from screening - What would U.S. patients and clinicians prefer, and do their preferences matter?预防宫颈癌与减少筛查危害——美国患者和临床医生更倾向于什么，他们的偏好重要吗？
Prev Med. 2017 May;98:31-32. doi: 10.1016/j.ypmed.2016.12.041. Epub 2017 Feb 6.
2
Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement.宫颈癌筛查：美国预防服务工作组推荐声明。
Ann Intern Med. 2012 Jun 19;156(12):880-91, W312. doi: 10.7326/0003-4819-156-12-201206190-00424.
3
HPV screening offers greater protection against invasive cervical cancer than cytology, finds analysis.分析发现，与人乳头瘤病毒（HPV）筛查相比，细胞学检查对浸润性宫颈癌的预防效果更佳。
BMJ. 2013 Nov 1;347:f6624. doi: 10.1136/bmj.f6624.
4
Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm.引入分子人乳头瘤病毒检测作为宫颈癌筛查的主要技术：依据证据改变当前模式。
Prev Med. 2017 May;98:5-14. doi: 10.1016/j.ypmed.2016.11.029. Epub 2017 Feb 6.
5
Cervical cancer screening and management practices among providers in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP).国家乳腺癌和宫颈癌早期检测项目（NBCCEDP）中医疗服务提供者的宫颈癌筛查与管理实践。
Cancer. 2007 Sep 1;110(5):1024-32. doi: 10.1002/cncr.22875.
6
A study of the impact of adding HPV types to cervical cancer screening and triage tests.一项关于将人乳头瘤病毒（HPV）类型纳入宫颈癌筛查和分流检测的影响的研究。
J Natl Cancer Inst. 2005 Jan 19;97(2):147-50. doi: 10.1093/jnci/dji014.
7
Perceived effectiveness of HPV test as a primary screening modality among US providers.美国医疗服务提供者对人乳头瘤病毒（HPV）检测作为主要筛查方式的感知效果。
Prev Med. 2015 Sep;78:33-7. doi: 10.1016/j.ypmed.2015.06.007. Epub 2015 Jun 24.
8
Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.发达国家和发展中国家基于人乳头瘤病毒及其他宫颈癌筛查新方法概述。
Vaccine. 2008 Aug 19;26 Suppl 10:K29-41. doi: 10.1016/j.vaccine.2008.06.019.
9
Human papillomavirus testing for primary cervical cancer screening.用于原发性宫颈癌筛查的人乳头瘤病毒检测
Expert Rev Mol Diagn. 2008 Sep;8(5):599-605. doi: 10.1586/14737159.8.5.599.
10
Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening.宫颈癌筛查中液基细胞学和人乳头瘤病毒检测的成本效益分析。
Obstet Gynecol. 2006 May;107(5):997-1005. doi: 10.1097/01.AOG.0000210529.70226.0a.
引用本文的文献
1
Role of Screening History in Clinical Meaning and Optimal Management of Positive Cervical Screening Results.筛查史在阳性宫颈筛查结果的临床意义和最佳管理中的作用。
J Natl Cancer Inst. 2019 Aug 1;111(8):820-827. doi: 10.1093/jnci/djy192.
2
The Next Generation of Cervical Cancer Screening: Should Guidelines Focus on Best Practices for the Future or Current Screening Capacity?下一代宫颈癌筛查：指南应关注未来的最佳实践还是当前的筛查能力？
J Low Genit Tract Dis. 2018 Apr;22(2):91-96. doi: 10.1097/LGT.0000000000000378.
3
HPV-based cervical cancer screening- facts, fiction, and misperceptions.基于人乳头瘤病毒的宫颈癌筛查——事实、虚构与误解
Prev Med. 2017 May;98:33-35. doi: 10.1016/j.ypmed.2016.12.040. Epub 2017 Feb 6.
4
Cervical cancer screening: Epidemiology as the necessary but not sufficient basis of public health practice.宫颈癌筛查：流行病学作为公共卫生实践的必要但不充分依据。
Prev Med. 2017 May;98:3-4. doi: 10.1016/j.ypmed.2016.12.028. Epub 2017 Feb 6.
本文引用的文献
1
Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm.引入分子人乳头瘤病毒检测作为宫颈癌筛查的主要技术：依据证据改变当前模式。
Prev Med. 2017 May;98:5-14. doi: 10.1016/j.ypmed.2016.11.029. Epub 2017 Feb 6.
2
The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen.每3年进行一次人乳头瘤病毒/细胞学联合宫颈筛查对人群的影响：降低宫颈癌风险并减少每次筛查中癌前病变的检出率。
Cancer. 2016 Dec 1;122(23):3682-3686. doi: 10.1002/cncr.30277. Epub 2016 Sep 22.
3
Increased cervical cancer risk associated with screening at longer intervals.宫颈癌风险增加与更长筛查间隔相关。
Obstet Gynecol. 2015 Feb;125(2):311-315. doi: 10.1097/AOG.0000000000000632.
4
Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.人乳头瘤病毒检测呈阴性可消除未来患癌前病变和癌症的风险。
J Natl Cancer Inst. 2014 Jul 18;106(8). doi: 10.1093/jnci/dju153. Print 2014 Aug.
5
Quality of life after complete lymphadenectomy for vulvar cancer: do women prefer sentinel lymph node biopsy?外阴癌行完全淋巴结清扫术后的生活质量：女性更倾向于前哨淋巴结活检吗？
Int J Gynecol Cancer. 2014 May;24(4):813-9. doi: 10.1097/IGC.0000000000000101.
6
ACOG Practice Bulletin Number 131: Screening for cervical cancer.ACOG 实践通报第 131 号：宫颈癌筛查。
Obstet Gynecol. 2012 Nov;120(5):1222-38. doi: 10.1097/aog.0b013e318277c92a.
7
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.美国癌症协会、美国阴道镜和宫颈病理学会以及美国临床病理学会宫颈癌预防和早期检测筛查指南。
J Low Genit Tract Dis. 2012 Jul;16(3):175-204. doi: 10.1097/LGT.0b013e31824ca9d5.
8
Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening.人乳头瘤病毒DNA检测作为子宫颈细胞学筛查辅助手段的临时指南。
Obstet Gynecol. 2004 Feb;103(2):304-9. doi: 10.1097/01.AOG.0000109426.82624.f8.
9
ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists. Number 45, August 2003. Cervical cytology screening (replaces committee opinion 152, March 1995).美国妇产科医师学会实践公告：妇产科临床管理指南。第45号，2003年8月。宫颈细胞学筛查（取代1995年3月委员会意见第152号）
Obstet Gynecol. 2003 Aug;102(2):417-27. doi: 10.1016/s0029-7844(03)00745-2.
Zotero 插件